Altasciences chosen by Virpax to conduct first-in-human study of Epoladerm™ for chronic pain associated with osteoarthritis of the knee | Virpax Pharmaceuticals

Jan 21, 2022

Altasciences chosen by Virpax to conduct first-in-human study of Epoladerm™ for chronic pain associated with osteoarthritis of the knee

admin2022-10-21T08:54:24-04:00January 21st, 2022|Media|

Nasdaq_Logo_wht

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

Nasdaq_Logo_wht

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

© Virpax^® Pharmaceuticals. All Rights Reserved.

© Virpax^® Pharmaceuticals. All Rights Reserved.

Follow @VirpaxPharma

Follow @VirpaxPharma